Is Apresitentan (Tryvio) reimbursed by health insurance? The latest medical insurance policy in 2025

Aprocitentan-Tryvio is a new anti-hypertensive drug that has been marketed in Europe and the United States. It has not yet obtained a drug approval number in mainland China, nor has it been included in the national medical insurance directory. This means that currently, if Chinese patients need treatment with Tryvio, they can only obtain drugs through overseas drug purchase, international medical services or cross-border medical channels. Because it is a new type of original drug, its price is relatively high and it is not covered by domestic medical insurance reimbursement, so patients face a high financial burden.

The main indication for Tryvio is refractory hypertension, which means that the patient's blood pressure still cannot reach the recommended target value even after being treated with at least three different classes of antihypertensive drugs (including diuretics). The clinical risk of such patients is significantly increased, and long-term hypertension can easily lead to serious consequences such as cardiac enlargement, arteriosclerosis, and renal failure. Therefore, the clinical value of Tryvio as a new target drug lies in providing new treatment ideas for this group of people for whom traditional drugs are ineffective.

In the international market, such as the United States, Europe and other places,Tryvio has been gradually included in the recommended use range of relevant hypertension guidelines. Although it is still in the stage of application for specific groups, its novel mechanism and good tolerability provide doctors with more medication options. At the same time, its price is also a key concern for patients. Because it is an imported original drug, it is often priced at a higher price range in overseas markets, which limits its widespread popularity.

From the perspective of domestic medical insurance policy, the inclusion of new drugs in medical insurance usually goes through the following processes: including State Food and Drug Administration approval, medical insurance catalog negotiation, pharmacoeconomic evaluation, clinical necessity analysis, etc. Since Tryvio has not yet been approved by the National Center for Drug Evaluation, it is currently unable to enter the medical insurance review stage.

Reference materials:https://go.drugbank.com/drugs/DB15059